PREVIEW
The benefits of aggressive cholesterol-lowering drug therapy are well established in patients with coronary heart disease (CHD) and other atherosclerotic disorders. But what about high-risk patients without clinical CHD? When is primary prevention appropriate for them? In this article, Dr Grundy discusses selection of high-risk patients for treatment and outlines therapeutic goals and drug options.